ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO079

A Tertiary Care Centre Experience of COVID-19-Associated AKI During the First and Second Waves of the Pandemic

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical‚ Outcomes‚ and Trials


  • Kumaresan, Maithrayie, University Hospital Lewisham, London, London, United Kingdom
  • Mogga, Phanidhar, MGM Healthcare, Chennai, Tamilnadu, India
  • Abraham, Georgi, MGM Healthcare, Chennai, Tamilnadu, India
  • Rajagopalan, Urjitha, MGM Healthcare, Chennai, Tamilnadu, India

There is a scarcity of information on the incidence and outcomes of acute kidney injury in COVID-19 patients in India. Therefore, we analysed the correlation of AKI risk factors and compared the outcomes of the first and second COVID-19 waves in a tertiary care centre.


●Single centre retrospective analysis
●Patients who tested positive for COVID-19 between July 2020 and May 2021, with serum creatinine levels measured on admission (n= 1260).
●AKI was defined according to the KDIGO clinical practice guidelines.
●Multivariate binomial logistic regression yielded odds ratios for risk variables of AKI.
●Age-adjusted odds ratios(OR) were used to compare COVID-19 outcomes between the first and second waves.


Baseline characteristics:
●Median Age= 56 (IQR 47-66)
●Population with diabetes-55.2%
●Population with hypertension-42.11%

All AKI (n=86)
●Stage 1 (n=57)
●Stage 2 (n=20)
●Stage 3 (n=9)

Risk factors for AKI:
●Diabetes OR 1.9 (1.2 – 3.1)
●Hypertension OR 3.2 (2.0 – 5.2)
●C-reactive protein ≥ 10 mg/dl, OR 3.6 (1.6 – 8.0).
●D-dimer ≥ 250 pg/ml, OR 4.2 (2.5 – 6.8).
●Need for ventilation OR 3.06 (1.8 – 4.9)

Comparison of COVID -19 outcomes:
Compared to the first wave, the second wave cohort had lower risk for:
●Acute kidney injury (adj OR: 0.4; CI: 0.2-0.7)
●Mortality (adj OR: 0.2; CI: 0.09-0.7)
●Invasive mechanical ventilation (adj OR: 0.2; CI: 0.06 - 0.8)
●Length of ICU stay > 5days (adj OR: 0.4; CI: 0.2 - 0.7)


In our retrospective study, AKI prevalence was 6.8%, and the mortality rate of 2.9%. Our analysis shows that the second wave of COVID -19 exhibits improved clinical outcomes compared to the first wave